TABLE 2.
Variant | Mean KD value (M [95% CI]) fora: |
|
---|---|---|
Tixagevimab | Cilgavimab | |
D614G | 7.57E−10 (5.4E−10, 1.1E−9) | <1E−12 (NE) |
Wild-type | 4.91E−10 (3.4E−10, 6.9E−10) | <1E−12 (NE) |
S494L:D614G | 8.55E−10 (6.0E−10, 1.2E−9) | 1.59E−8 (1.1E−8, 2.2E−8) |
K444R:D614G | 5.37E−10 (3.8E−10, 7.5E−10) | NA (NE) |
F486S:D614G | NB (NE) | <1E−12 (NE) |
F486W:D614G | NA (NE) | <1E−12 (NE) |
KD, equilibrium dissociation constant; M, mol/L; CI, confidence interval; NE, 95% CI was not evaluable; NA, not available due to poor binding with inaccurate curve fitting; NB, no binding. 1E−12 M was used for KD values of <1E−12 M, and 95% CI was not calculated for variants with a mean KD of <1E−12 M.